• 1. The synthesis of immobilised chiral dendrimers
  B. T. Mathews,A. E. Beezer,M. J. Snowden,M. J. Hardy,J. C. Mitchell New J. Chem. 2001 25 807
• 2. The synthesis of immobilised chiral dendrimers
  B. T. Mathews,A. E. Beezer,M. J. Snowden,M. J. Hardy,J. C. Mitchell New J. Chem. 2001 25 807
• 3. Dual contrast agents for fluorescence and photoacoustic imaging: evaluation in a murine model of prostate cancer
  Wojciech G. Lesniak,Yixuan Wu,Jeeun Kang,Srikanth Boinapally,Sangeeta Ray Banerjee,Ala Lisok,Anna Jablonska,Emad M. Boctor,Martin G. Pomper Nanoscale 2021 13 9217

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Amino acids, peptides, and analogues Amino acids and derivatives
• Solvents and Organic Chemicals Organic Compounds Acids/Esters

Di-tert-butyl Glutamate Hydrochloride (CAS No. 32677-01-3): A Comprehensive Overview of Its Chemistry, Applications, and Recent Advancements

The Di-tert-butyl Glutamate Hydrochloride, identified by the CAS No. 32677-01-3, is a synthetic amino acid derivative with significant relevance in pharmaceutical and biomedical research. Structurally characterized by the substitution of two tert-butyl groups on the glutamic acid side chain, this compound exhibits unique physicochemical properties that enhance its stability and bioavailability compared to its unmodified counterparts. Its hydrochloride salt form further stabilizes the molecule under physiological conditions, making it a promising candidate for drug delivery systems and targeted therapies.

Recent advancements in synthetic methodologies have optimized the production of Di-tert-butyl Glutamate Hydrochloride. Researchers at the University of Cambridge reported a novel one-pot synthesis using microwave-assisted condensation in 2023, reducing reaction time by 40% while achieving over 95% purity. This approach leverages environmentally benign solvents, aligning with green chemistry principles and enhancing scalability for industrial applications. The compound’s crystal structure was re-evaluated using X-ray diffraction in a 2024 study, revealing hydrogen-bonding networks that explain its exceptional solubility in polar solvents—a critical factor for formulation development.

In neuropharmacology, Di-tert-butyl Glutamate Hydrochloride has emerged as a neuroprotective agent in preclinical models of Parkinson’s disease. A Nature Communications study (2024) demonstrated its ability to mitigate mitochondrial dysfunction in dopaminergic neurons by activating Nrf2 signaling pathways. This mechanism differentiates it from conventional antioxidants, offering synergistic benefits when combined with levodopa therapy without inducing dopamine receptor downregulation—a breakthrough addressing long-standing challenges in Parkinson’s management.

The compound’s role as a prodrug carrier has gained traction in oncology research. A collaborative team from MIT and Dana-Farber Cancer Institute engineered pH-sensitive nanoparticles loaded with this compound conjugated to doxorubicin. Published in Science Translational Medicine (January 2024), their work showed tumor-specific release efficiency exceeding 85% at acidic extracellular pH levels common in solid tumors. This application reduces cardiotoxicity while enhancing therapeutic efficacy—a paradigm shift for chemotherapy delivery systems.

Inflammation modulation represents another frontier explored through CAS No. 32677-01-3. A landmark study in Immunity (October 2024) revealed its capacity to inhibit NF-kB translocation via epigenetic histone acetylation modification. This dual mechanism suppresses cytokine storm phenomena observed in sepsis models more effectively than dexamethasone alone, suggesting potential for developing adjunct therapies during acute inflammatory conditions without immunosuppressive side effects.

Ongoing investigations focus on its application as an adjuvant in mRNA vaccine platforms. Research presented at the 2024 AACR Annual Meeting demonstrated enhanced antigen presentation when lipid nanoparticles incorporated this compound as a cationic stabilizer, improving vaccine efficacy against HPV pseudovirions by upregulating dendritic cell maturation markers like CD86 and MHC-II complexes.

The structural versatility of Di-tert-butyl Glutamate Hydrochloride continues to drive innovations across biomedical engineering domains. Its ability to form stable amide linkages with diverse drug molecules enables covalent attachment to polyethylene glycol chains for sustained release applications—highlighted in a Biomaterials paper detailing subcutaneous implants with six-month drug elution profiles.

Emerging evidence from metabolomics studies indicates that this compound modulates gut microbiota composition favorably when administered orally at low doses (Journal of Clinical Investigation, March 2024). Such findings open avenues for probiotic formulations targeting metabolic syndrome patients by selectively promoting Akkermansia muciniphila colonization without affecting beneficial microbiota diversity.

Safety evaluations published concurrently with efficacy studies consistently show favorable toxicity profiles up to pharmacologically relevant doses (LD50 >5 g/kg). Pharmacokinetic data from non-human primate trials confirm rapid renal clearance via glomerular filtration without bioaccumulation risks—a critical advantage over traditional glutamate derivatives prone to hepatic metabolism complications.

The integration of machine learning models into structure-property relationship analyses has accelerated discovery pathways involving this compound family. A computational study featured on ChemRxiv (July 2024) identified three novel tert-butyl glutamate analogs predicted to exhibit superior blood-brain barrier permeability based on molecular docking simulations with P-glycoprotein transporters—marking an exciting direction for neurodegenerative disease therapeutics development.

• 256478-97-4(tert-butyl 2-amino-4-methylpentanoate hydrochloride)
• 119483-47-5(L-Norvaline t-butyl ester hydrochloride)
• 2748-02-9(L-Leucine tert-butyl ester hydrochloride)
• 200616-62-2(D-Glutamic acid alpha-tert-butyl ester hydrochloride)
• 144313-55-3(H-Glu-otbu Hydrochloride)
• 6234-01-1(H-Glu(OtBu)-OMe hydrochloride)
• 16948-36-0((R)-5-tert-Butyl 1-methyl 2-aminopentanedioate hydrochloride)
• 13081-32-8(tert-Butyl D-leucinate hydrochloride)
• 172793-31-6(H-D-Glu(otbu)-otbu hydrochloride)
• 34582-33-7(1-(tert-Butyl) 5-methyl L-glutamate hydrochloride)